Clinical trials: Helicobacter
Colorectal Cancer, Stomach Disease
Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
1. The abundant results from this trial will be helpful for assessing the feasibility of increasing stool sampling and shortening screening interval in population setting for lower and upper gastrointestinal tract lesions, their…
- Trial name
- NCT01741363
- Testing
- FIT(Eiken OC-Sensor) Two-day sampling, FIT(Eiken OC-Sensor) One-year interval, FIT(Eiken OC-Sensor) One-day sampling
- Where
- Taiwan
- Volunteers
- 99,314 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Helicobacter Pylori Infection
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing quadruple therapy was suggested to be the first choice for eradication therapy of Helicobacter pylori in the area with high clarithromycin…
- Trial name
- NCT02541864
- Testing
- Bismuth quadruple therapy, Hybrid therapy
- Volunteers
- 330 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
- Trial name
- NCT02905825
- Testing
- BreathID® Hp System, BreathID® Hp Lab System, Stool Test
- Where
- 6 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.
- Trial name
- NCT04198363
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- 29 sites in China
- Volunteers
- 510 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea. 2. To evaluate the effect of H.
- Trial name
- NCT02159976
- Testing
- Pantoprazole, Amoxicillin, Clarithromycin
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Seoul National University Bundang Hospital
Dyspepsia, Helicobacter Pylori Infection
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp (NCT01980095)
- Testing
- RHB-105
- Where
- 12 sites in United States
- Volunteers
- 119 people
- Sponsor
- RedHill Biopharma Limited
Helicobacter Pylori Infection
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Reverse hybrid therapy is a one-step two-phase treatment for Helicobacter pylori infection with less cost than standard triple therapy.
- Trial name
- REHYTRI (NCT02359435)
- Testing
- Reverse hybrid therapy, Standard triple therapy
- Where
- Taiwan
- Volunteers
- 440 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
This phase Ⅰb/Ⅱa, single-center, randomized, open-label study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary Helicobacter Pylori eradication efficacy in asymptomatic subjects with…
- Trial name
- NCT06076681
- Testing
- TNP-2198, Rabeprazole Sodium, Amoxicillin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infection
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
This is a single-center, randomized, open-label phase Ic/IIb clinical study to evaluate the efficacy and safety of TNP-2198 capsules, rabeprazole sodium enteric-coated tablets and amoxicillin capsules combined with multiple doses…
- Trial name
- NCT06076694
- Testing
- TNP-2198, Rabeprazole Sodium, Amoxicillin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infection
A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects
This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study.
- Trial name
- NCT06190340
- Testing
- TNP-2092 capsules
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Helicobacter Pylori Infection
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available.
- Trial name
- NCT02596620
- Testing
- Nexium, Amolin, Cravit
- Volunteers
- 164 people
- Sponsor
- Chang Gung Memorial Hospital
Gastric Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
- Trial name
- NCT03050307
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 234 people
- Sponsor
- Takeda
Helicobacter Pylori
A Study of Vonoprazan in Adults With Helicobacter Pylori
Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other parts of the digestive system.
- Trial name
- NCT04753437
- Testing
- Clarithromycin, Amoxicillin, Bismuth potassium citrate
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Takeda
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Infection, Achlorhydria
Clinical Experiment of Helicobacter Pylori Transmission
The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli.
- Trial name
- NCT00550368
- Testing
- Biological intervention: Enteropathogenic E. coli
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01654549
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences